AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.
We believe that OMIC technologies represent an important first step towards gaining biological insights into:
Aromics participates at EMTECH Spain forum
Emtech Spain 2012 closed the past 23thof November with one of the most relevant activities: the Investors...
http://www.youtube.com/user/technologyreviewes
Aromics participates in the Meeting for future PhD students
Dr. Carme Plasencia, CSO of AROMICS, participated last 25th October, on the round table...
With 35,000 genes and hundreds of thousands of protein states to identify, correlate, and characterize, the studies of one gene, gene product, or process are no longer reliable or cost-effective. We have entered the "omic" era in biology. But large- scale omic studies of cellular molecules in aggregate rarely answer interesting questions without the assistance of information from traditional hypothesis- driven research. These scientific methods are complementary and synergistic.
John N. Weinstein. Disease Markers 17(2): 77- 88, 2001.
